Target intelligence / Profile preview

Influenza A virus H1N1 hemagglutinin globular head (HA1-GH) (HA1-GH)

Target
HA1-GH
Molecular classification
Viral glycoprotein [1, 8], Receptor-binding protein [1, 22], Class I fusion protein subunit [8, 10]
01

Overview

The globular head of the Influenza A H1N1 hemagglutinin (HA) is the membrane-distal domain of the HA1 subunit, primarily responsible for viral attachment to host cells [1, 8]. It contains the receptor binding site (RBS), which recognizes and binds to terminal sialic acid residues on host cell surface glycoproteins, initiating viral entry via endocytosis [1, 22]. This domain is also the primary target for neutralizing antibodies elicited by seasonal vaccines and natural infection, making it a critical component of the host immune response [11, 13]. However, the globular head is characterized by high genetic plasticity and frequent mutations, a process known as antigenic drift, which allows the virus to evade pre-existing immunity [1, 12, 13]. Therapeutic strategies targeting this domain include monoclonal antibodies that block the RBS and small molecule or peptide inhibitors designed to mimic sialic acid or interfere with the binding pocket [3, 16, 22]. Because of its role in host specificity and immune evasion, the globular head remains a focal point for the development of next-generation vaccines and entry inhibitors [7, 21].

Other names
Hemagglutinin HA1 subunit [4, 7]Hemagglutinin globular head domain [1, 15]Receptor binding domain of hemagglutinin (HA1-RBD) [1, 18]H1N1 HA1 [9, 12]
02

Mechanism of action

Inhibition of viral attachment by blocking the receptor binding site (RBS) on the globular head, preventing interaction with host cell sialic acid receptors [1, 3, 22].

03

Biological functions

Viral attachment [1, 8]Host cell recognition [1, 22]Immune response induction [11, 13]Receptor binding [1, 18]
04

Disease associations

Infection [1, 6]Influenza A [1, 9]Pandemic influenza [1, 9]Seasonal influenza [1, 9]
05

Safety considerations

Antigenic drift leading to vaccine/drug escape [1, 12, 13]High mutation rate in the globular head [7, 16, 21]Potential for antibody-dependent enhancement (ADE) [14, 20]
06

Interacting drugs

Umifenovir (Arbidol) [1, 15, 27]

6 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HI) titer [12, 20, 24]Anti-HA antibody concentration [13, 14]Viral load (RNA) [14, 27]Sialic acid binding affinity [18, 22]

Beyond the preview

Go deeper on Influenza A virus H1N1 hemagglutinin globular head (HA1-GH) (HA1-GH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus H1N1 hemagglutinin globular head (HA1-GH) (HA1-GH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call